42150 Stories, most recent news story added 41 seconds ago
NEW YORK (AP) -- Shares of some top managed care companies were up at the close of trading: Aetna rose $1.08 or 3.8 percent, to $29.48. CIGNA rose $2.27 or 7.6 percent, to $32.30. Coventry Healthcare rose $.79 or 3.5 percent, to $23.33. Humana rose $1.04 or 2.6 percent, to $41.48. UnitedHealth rose $.52 or 1.8 percent, to $29.08. WellPoint rose $2.38 or 4.6 percent, to $54.52.
NEW YORK (AP) -- Shares of some top managed care companies are up at noon: Aetna rose $1.07 or 3.8 percent, to $29.47. CIGNA rose $2.16 or 7.2 percent, to $32.19. Coventry Healthcare rose $.92 or 4.1 percent, to $23.46. Humana rose $1.28 or 3.2 percent, to $41.72. UnitedHealth rose $.59 or 2.1 percent, to $29.15. WellPoint rose $2.13 or 4.1 percent, to $54.27.
If UnitedHealthcare acquires the Northeast operations of its smaller competitor Health Net, the larger insurer won't provide enough coverage in rural areas, will control a lopsided share of the Fairfield County medical market, will likely increase premiums and balk at covering needed services, doctor groups and consumer advocates said Monday.
Besting Humana and Aetna with a lower bid, Blue Cross Blue Shield of Michigan will continue to manage the health services of more than 196,000 retired school employees and their dependents after the state of Michigan earlier...
NEW YORK (AP) -- Shares of some top managed care companies are up at 10 a.m.: Aetna rose $1.16 or 4.1 percent, to $29.56. CIGNA rose $2.10 or 7.0 percent, to $32.13. Coventry Healthcare rose $.75 or 3.3 percent, to $23.29. Humana rose $1.23 or 3.0 percent, to $41.67. UnitedHealth rose $.80 or 2.8 percent, to $29.36. WellPoint rose $2.28 or 4.4 percent, to $54.42.
Direct-to-consumer advertising for a commonly prescribed antiplatelet drug does not appear associated with increased use, but may be associated with increased drug costs and Medicaid pharmacy expenditures, according to a new report.
When consumer advertising began for the popular blood-thinner Plavix, Medicaid insurance programs for the poor and disabled spent millions more on the drug, even though the ads did not tempt doctors to write more prescriptions, researchers reported on Monday.
LOS ANGELES----Health Net, Inc. today announced that it is rescheduling its annual Investor Day from December 11, 2009, to February 11, 2010. The company expects to issue its 2010 earnings guidance on December 11, 2009.
WHITEHOUSE STATION, N.J. - Merck & Co. said Monday a district court judge in Texas dismissed all claims in a state Medicaid lawsuit over the painkiller Vioxx.
MONDAY, Nov. 23 (HealthDay News) -- The fallout from last week's controversial recommendation that women delay the start of routine mammogram testing for breast cancer continues, with a former head of the U.S. National Institutes of Health advising women to ignore the guidelines.
Kaiser Permanente has the top-ranked Medicare health plan in the nation, according to a joint ranking by U.S. News & World Report and the National Committee for Quality Assurance.
Aetna Government Health Plans of Hartford, Conn., appears to have gained an unfair advantage in competing for TRICARE’s North Region support contract, valued at $16.7 billion, by hiring a former chief of staff at TRICARE headquarters to help the company draft its winning proposal.
Palmetto General Hospital announced that it has received 10 CIGNA quality designations for 2009. These designations mean the hospital has met rigorous quality criteria based on nationally- recognized medical standards and expert advice.
Tomah Memorial Hospital, along with other Critical Access Hospitals (CAHs) across the state, will see a 10 percent reduction in Wisconsin Medicaid reimbursements beginning Jan. 1, as part of a state budget provision aimed at filling a $600-million gap in the state’s Medicaid program.
Federal health officials are trying to shift supplies of the seasonal flu vaccine away from chain pharmacies and supermarkets to nursing homes.
A study proposes a broad model for monitoring drug safety that would consist of detailed publicly available data that independent researchers could freely analyze.
Open slideshowReuters
Open slideshowReuters
Open slideshowReuters
Open slideshowReuters
